Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Posts 7 Percent Q2 Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues grew 7 percent, led by its BD Medical segment

The Franklin Lakes, NJ-based firm reported total revenues of $1.84 billion for the three-month period ended March 31, compared to $1.72 billion for Q1 2009. The firm fell just short of analysts' consensus expectations for revenues of $1.85 billion.

The firm's BD Medical segment had 9 percent revenue growth to $967.1 million compared to $881.5 million; its BD Biosciences business had 6 percent revenue growth to $322.1 million from $303.8 million; and its BD Diagnostics segment had 3 percent revenue growth to $555.7 million from $539.6 million.

Within BD Biosciences, its cell analysis revenues rose 9 percent to $78.2 million from $71.8 million, and its discovery labware products brought in $39 million, up 21 percent from $32.3 million for Q1 2009.

"Solid revenue growth in our Medical segment and a continued improvement in our Biosciences segment offset lower-than-expected growth in our Diagnostics segment," Edward Ludwig, chairman and CEO of BD, said in a statement.

BD posted a profit of $297.6 million, or $1.24 per share, versus $261.3 million, or 1.06 per share. It beat analysts' expectations by a penny.

Its R&D spending for the quarter rose nearly 3 percent to $101.1 million from $98.6 million, while its SG&A spending fell around 2 percent to $426.3 million from $436.4 million.

BD expects to report full-year 2010 revenue growth of 6 percent, 1 percent lower than previously expected due to currency fluctuations.

In early afternoon trade on the New York Stock Exchange, shares of BD were down less than 1 percent at $76.50.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.